Literature DB >> 27811505

Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.

Sjoerd Nell1, Inne H M Borel Rinkes2, Helena M Verkooijen3, Bert A Bonsing4, Casper H van Eijck5, Harry van Goor6, Ruben H J de Kleine7, Geert Kazemier8, Elisabeth J Nieveen van Dijkum9, Cornelis H C Dejong10, Gerlof D Valk11, Menno R Vriens12.   

Abstract

OBJECTIVE: To estimate short and long-term morbidity after pancreatic surgery for multiple endocrine neoplasia type 1 (MEN1)-related nonfunctioning pancreatic neuroendocrine tumors (NF-pNETs).
BACKGROUND: Fifty percent of the MEN1 patients harbor multiple NF-pNETs. The decision to proceed to NF-pNET surgery is a balance between the risk of disease progression versus the risk of surgery-related morbidity. Currently, there are insufficient data on the surgical complications after MEN1 NF-pNET surgery.
METHODS: MEN1 patients diagnosed with a NF-pNET who underwent surgery were selected from the DutchMEN1 study group database, including >90% of the Dutch MEN1 population. Early postoperative complications, new-onset diabetes mellitus, and exocrine pancreatic insufficiency were captured.
RESULTS: Sixty-one patients underwent NF-pNET surgery at 1 of the 8 Dutch academic centers. Patients were young (median age 41 years) with low American Society of Anesthesiologists scores. Median NF-pNET size on imaging was 22 mm (3-157). Thirty-three percent (19/58) of the patients developed major early-Clavien-Dindo grade III to IV-complications mainly consisting International Study Group of Pancreatic Surgery grade B/C pancreatic fistulas. Twenty-three percent of the patients (14/61) developed endocrine or exocrine pancreas insufficiency. The development of major early postoperative complications was independent of the NF-pNET tumor size. Twenty-one percent of the patients (12/58) developed multiple major early complications.
CONCLUSIONS: MEN1 NF-pNET surgery is associated with high rates of major short and long-term complications. Current findings should be taken into account in the shared decision-making process when MEN1 NF-pNET surgery is considered.

Entities:  

Mesh:

Year:  2018        PMID: 27811505     DOI: 10.1097/SLA.0000000000002050

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

Review 1.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

Review 2.  Diagnosis and Management of Exocrine Pancreatic Insufficiency.

Authors:  Chris E Forsmark
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

Review 3.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 4.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

5.  One-Year Postoperative Mortality in MEN1 Patients Operated on Gastric and Duodenopancreatic Neuroendocrine Tumors: An AFCE and GTE Cohort Study.

Authors:  Niki Christou; Muriel Mathonnet; Sébastien Gaujoux; Guillaume Cadiot; Sophie Deguelte; Jean-Louis Kraimps; Jean-Christophe Lifante; Fabrice Menegaux; Eric Mirallié; Fabrice Muscari; Bruno Carnaille; François Pattou; Alain Sauvanet; Pierre Goudet
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

Review 6.  Recent Topics Around Multiple Endocrine Neoplasia Type 1.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

7.  Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort.

Authors:  Dirk-Jan van Beek; Helena M Verkooijen; Sjoerd Nell; Bert A Bonsing; Casper H van Eijck; Harry van Goor; Frederik J H Hoogwater; Elisabeth J M Nieveen van Dijkum; Geert Kazemier; Cornelis H C Dejong; Lodewijk A A Brosens; Frank J Wessels; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens
Journal:  Neuroendocrinology       Date:  2020-07-28       Impact factor: 4.914

8.  Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort.

Authors:  Dirk-Jan van Beek; Sjoerd Nell; Wessel M C M Vorselaars; Bert A Bonsing; Casper H J van Eijck; Harry van Goor; Elisabeth J Nieveen van Dijkum; Cornelis H C Dejong; Gerlof D Valk; Inne H M Borel Rinkes; Menno R Vriens
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

9.  Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.

Authors:  Dirk-Jan van Beek; Sjoerd Nell; Helena M Verkooijen; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens
Journal:  Surgery       Date:  2020-11-19       Impact factor: 4.348

Review 10.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.